ABT-239

• UNSPSC Description:

  ABT-239 is a novel, highly efficacious, non-imidazole?class of H3R antagonist and a transient receptor potential vanilloid type 1 (TRPV1) antagonist.?

• Target Antigen:

  Histamine Receptor; TRP Channel

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Immunology/Inflammation;Membrane Transporter/Ion Channel;Neuronal Signaling

• Field of Research:

  Neurological Disease; Endocrinology

• Assay Protocol:

  https://www.medchemexpress.com/ABT-239.html

• Purity:

  99.23

• Solubility:

  DMSO : ≥ 100 mg/mL|H2O : < 0.1 mg/mL

• Smiles:

  C[C@H]1N(CCC2=CC3=C(C=CC(C4=CC=C(C#N)C=C4)=C3)O2)CCC1

• Molecular Weight:

  330.42

• References & Citations:

  [1]Bhowmik M, et al. Histamine H3 receptor antagonism by ABT-239 attenuates kainic acid induced excitotoxicity in mice. Brain Res. 2014 Sep 18;1581:129-40.|[2]Provensi G, et al. Donepezil, an acetylcholine esterase inhibitor, and ABT-239, a histamine H3 receptor antagonist/inverse agonist, require the integrity of brain histamine system to exert biochemical and procognitive effects in the mouse. Neuropharmacolo|[3]Kruk M, e tal. Effects of the histamine H2 receptor antagonist ABT-239 on cognition and nicotine-induced memory enhancement in mice. Pharmacol Rep. 2012;64(6):1316-25.|[4]Munari L, et al. Selective brain region activation by histamine H2 receptor antagonist/inverse agonist ABT-239 enhances acetylcholine and histamine release and increases c-Fos expression. Neuropharmacology. 2013 Jul;70:131-40.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Phase 1

• CAS Number:

  460746-46-7